127 related articles for article (PubMed ID: 31013221)
1. Unusual Drug Fever Caused by Imipenem/Cilastatin and a Review of Literature.
Yang J; Wang Q; Wang S; Zhang Y; Wang Z
Heart Surg Forum; 2019 Mar; 22(2):E119-E123. PubMed ID: 31013221
[TBL] [Abstract][Full Text] [Related]
2. Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.
Arnold HM; McKinnon PS; Augustin KM; Hladnik LM; Casabar E; Reichley RM; Dubberke ER; Westervelt P; Ritchie DJ
Pharmacotherapy; 2009 Aug; 29(8):914-23. PubMed ID: 19637944
[TBL] [Abstract][Full Text] [Related]
3. Reversible black tongue: A little known side effect of imipenem/cilastatin and evidence for novel mode of action.
Zhao S; Fan L; Feng J; Ma P
J Clin Pharm Ther; 2020 Apr; 45(2):370-372. PubMed ID: 31621928
[TBL] [Abstract][Full Text] [Related]
4. Imipenem-cilastatin-induced psychosis: a case report.
Ninan J; George GM
J Med Case Rep; 2016 Apr; 10(1):107. PubMed ID: 27118305
[TBL] [Abstract][Full Text] [Related]
5. Randomised study comparing imipenem/cilastatin to ceftriaxone plus gentamicin in cancer chemotherapy-induced neutropenic fever.
Au E; Tow A; Allen DM; Ang PT
Ann Acad Med Singap; 1994 Nov; 23(6):819-22. PubMed ID: 7741492
[TBL] [Abstract][Full Text] [Related]
6. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients.
Shah PM; Heller A; Fuhr HG; Walther F; Halir S; Schaumann R; Böhme A; Jung B; Köhler A; Lips-Schulte C; Stille W
Infection; 1996; 24(6):480-4. PubMed ID: 9007599
[TBL] [Abstract][Full Text] [Related]
7. Risk/benefit in the treatment of children with imipenem-cilastatin for meningitis caused by penicillin-resistant pneumococcus.
Asensi F; Otero MC; Pérez-Tamarit D; Rodríguez-Escribano I; Cabedo JL; Gresa S; Cantón E
J Chemother; 1993 Apr; 5(2):133-4. PubMed ID: 8515296
[TBL] [Abstract][Full Text] [Related]
8. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer).
Biron P; Fuhrmann C; Cure H; Viens P; Lefebvre D; Thyss A; Viot M; Soler-Michel P; Rollin C; Grès JJ
J Antimicrob Chemother; 1998 Oct; 42(4):511-8. PubMed ID: 9818751
[TBL] [Abstract][Full Text] [Related]
9. [Comparative study of piperacillin/tazobactam versus imipenem/cilastatin in febrile neutropenia (1994-1996)].
Figuera A ; Rivero N; Pajuelo F; Font P; Leyra F; de La Cámara R; Arranz R; María Fernández Rañada J
Med Clin (Barc); 2001 May; 116(16):610-1. PubMed ID: 11412645
[TBL] [Abstract][Full Text] [Related]
10. Imipenem/cilastatin treatment of bacterial meningitis in children.
Wong VK; Wright HT; Ross LA; Mason WH; Inderlied CB; Kim KS
Pediatr Infect Dis J; 1991 Feb; 10(2):122-5. PubMed ID: 2062603
[TBL] [Abstract][Full Text] [Related]
11. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin.
Calandra G; Lydick E; Carrigan J; Weiss L; Guess H
Am J Med; 1988 May; 84(5):911-8. PubMed ID: 3284342
[TBL] [Abstract][Full Text] [Related]
12. Vertigo caused by intravenous imipenem/cilastatin.
Duque A; Altimiras J; García-Cases C; Vidal P
DICP; 1991 Sep; 25(9):1009. PubMed ID: 1949961
[No Abstract] [Full Text] [Related]
13. Trimethoprim-sulfamethoxazole plus amikacin as first-line therapy and imipenem/cilastatin as second empirical therapy in febrile neutropenic patients with hematological disorders.
Engervall PA; Stiernstedt GT; Günther GC; Björkholm MJ
J Chemother; 1992 Apr; 4(2):99-106. PubMed ID: 1629753
[TBL] [Abstract][Full Text] [Related]
14. Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin.
Karadeniz C; Oğuz A; Canter B; Serdaroğlu A
Pediatr Hematol Oncol; 2000; 17(7):585-90. PubMed ID: 11033734
[TBL] [Abstract][Full Text] [Related]
15. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
[TBL] [Abstract][Full Text] [Related]
16. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group.
Eklund AE; Nord CE
J Antimicrob Chemother; 1993 Jan; 31 Suppl A():79-85. PubMed ID: 8383657
[TBL] [Abstract][Full Text] [Related]
17. Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group.
Norrby SR; Finch RG; Glauser M
J Antimicrob Chemother; 1993 Jun; 31(6):927-37. PubMed ID: 8360130
[TBL] [Abstract][Full Text] [Related]
18. Seizure-like activity associated with imipenem-cilastatin.
Tse CS; Hernandez Vera F; Desai DV
Drug Intell Clin Pharm; 1987; 21(7-8):659-60. PubMed ID: 3608817
[No Abstract] [Full Text] [Related]
19. Severe neutropenia in a patient treated with imipenem/cilastatin.
Fariñas MC; de Vega T; Garmendia J; González-Macías J
Eur J Clin Microbiol Infect Dis; 1993 Apr; 12(4):303-4. PubMed ID: 8513823
[No Abstract] [Full Text] [Related]
20. Treatment of tularemia with imipenem/cilastatin sodium.
Lee HC; Horowitz E; Linder W
South Med J; 1991 Oct; 84(10):1277-8. PubMed ID: 1925735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
